Pharmaceutical companies are raising list prices on at least 350 branded medicines in the United States for 2026, an increase in the number of hikes compared with about 250 drugs at the same point a year earlier. The changes affect a wide range of products, including vaccines for COVID‑19 and shingles, cancer therapies, and treatments for conditions such as migraine and diabetes.
According to data provided to independent analysts, the median list‑price increase is around 4%, roughly in line with the median hike seen in 2025. These figures refer to list prices before rebates and discounts negotiated with pharmacy benefit managers and insurers, so the ultimate impact on patient out‑of‑pocket costs may differ by plan design.
Several large manufacturers account for a significant share of the increases, with one major company alone planning adjustments on roughly 80 medicines and vaccines. A smaller group of products will see list‑price cuts, including a notable reduction of more than 40% for the diabetes drug Jardiance, which is among the first medicines to receive a negotiated Medicare price for 2026. Policymakers and payers are expected to scrutinize how these list‑price moves interact with new Medicare drug‑pricing provisions taking effect this year.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!